Roquefort Investments PLC (ROQ) - Net Assets
Based on the latest financial reports, Roquefort Investments PLC (ROQ) has net assets worth GBX4.75 Million GBX (≈ $578.29 USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX5.66 Million ≈ $688.91 USD) and total liabilities (GBX909.12K ≈ $110.61 USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read ROQ total debt and obligations for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX4.75 Million |
| % of Total Assets | 83.94% |
| Annual Growth Rate | 6.19% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 44.57 |
Roquefort Investments PLC - Net Assets Trend (2021–2024)
This chart illustrates how Roquefort Investments PLC's net assets have evolved over time, based on quarterly financial data. Also explore ROQ current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Roquefort Investments PLC (2021–2024)
The table below shows the annual net assets of Roquefort Investments PLC from 2021 to 2024. For live valuation and market cap data, see Roquefort Investments PLC market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | GBX4.89 Million ≈ $594.85 |
-11.10% |
| 2023-12-31 | GBX5.50 Million ≈ $669.14 |
-23.69% |
| 2022-12-31 | GBX7.21 Million ≈ $876.84 |
+76.52% |
| 2021-12-31 | GBX4.08 Million ≈ $496.74 |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Roquefort Investments PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 435075000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX1.36 Million | 27.76% |
| Other Comprehensive Income | GBX4.18 Million | 85.43% |
| Other Components | GBX4.62 Million | 94.49% |
| Total Equity | GBX4.89 Million | 100.00% |
Roquefort Investments PLC Competitors by Market Cap
The table below lists competitors of Roquefort Investments PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lipella Pharmaceuticals Inc. Common Stock
NASDAQ:LIPO
|
$184.37K |
|
CleanTech Lithium plc
LSE:CTL
|
$185.19K |
|
Northern Bear Plc
LSE:NTBR
|
$185.84K |
|
Fang Holdings Ltd
NYSE:SFUNY
|
$186.18K |
|
Ratu Prabu Energi Tbk
JK:ARTI
|
$183.76K |
|
Trustco Group Holdings
JSE:TTO
|
$182.74K |
|
Sable Exploration and Mining Ltd
JSE:SXM
|
$180.37K |
|
Greenroc Mining PLC
LSE:GROC
|
$180.09K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Roquefort Investments PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,499,543 to 4,889,019, a change of -610,524 (-11.1%).
- Net loss of 971,803 reduced equity.
- Other comprehensive income increased equity by 78,714.
- Other factors increased equity by 282,565.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-971.80K | -19.88% |
| Other Comprehensive Income | GBX78.71K | +1.61% |
| Other Changes | GBX282.56K | +5.78% |
| Total Change | GBX- | -11.10% |
Book Value vs Market Value Analysis
This analysis compares Roquefort Investments PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 246.02x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 55.97x to 246.02x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | GBX0.17 | GBX9.25 | x |
| 2022-12-31 | GBX0.07 | GBX9.25 | x |
| 2023-12-31 | GBX0.04 | GBX9.25 | x |
| 2024-12-31 | GBX0.04 | GBX9.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Roquefort Investments PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.88%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.18x
- Recent ROE (-19.88%) is above the historical average (-24.12%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -22.47% | -127598.47% | 0.00x | 1.12x | GBX-1.33 Million |
| 2022 | -22.42% | 0.00% | 0.00x | 1.08x | GBX-2.34 Million |
| 2023 | -31.72% | -872.27% | 0.03x | 1.11x | GBX-2.29 Million |
| 2024 | -19.88% | 0.00% | 0.00x | 1.18x | GBX-1.46 Million |
Industry Comparison
This section compares Roquefort Investments PLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $8,864,748
- Average return on equity (ROE) among peers: -251.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Roquefort Investments PLC (ROQ) | GBX4.75 Million | -22.47% | 0.19x | $184.27K |
| 4BASEBIO UK SOCIETAS (4BB) | $7.12 Million | -72.33% | 0.64x | $951.45K |
| Aptamer Group PLC (APTA) | $245.81K | -274.50% | 4.65x | $205.09K |
| Arecor Therapeutics PLC (AREC) | $5.35 Million | -191.36% | 0.63x | $303.20K |
| Avacta Group PLC (AVCT) | $29.89 Million | -21.30% | 0.06x | $3.99 Million |
| BSF Enterprise Plc (BSFA) | $3.58 Million | -25.96% | 0.13x | $27.33K |
| Bioventix (BVXP) | $11.01 Million | 51.43% | 0.08x | $1.10 Million |
| Cizzle Biotechnology Holdings PLC (CIZ) | $32.00K | -956.25% | 1.81x | $127.81K |
| Amur Minerals Corporation (CRTX) | $20.48 Million | -8.91% | 0.04x | $80.26K |
| Fusion Antibodies PLC (FAB) | $50.13K | -935.06% | 5.06x | $193.60K |
| Faron Pharmaceuticals Oy (FARN) | $10.88 Million | -85.40% | 0.59x | $575.13K |
About Roquefort Investments PLC
Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy and toxicology studies, as well as orphan drug indication; Midkine RNA oligonucleotide therapeutics with nov… Read more